12,372 trials
Overactive Bladder
Primary: Change From Baseline at Week 12 in the Average Number of Micturition Episodes Per Day — -2.04; -1.30 Micturitions per day — p=<0.0001
Epithelial Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
Primary: Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors…
Clostridium Difficile Infection · Infection · Communicable Diseases
Primary: Safety and Tolerability of RBX2660 in Subjects With Recurrent CDI. — 697 Participants
Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Complete Response (CR) — 67; 18 percentage of participants — p=<0.001
Chronic Heart Failure (CHF)
Primary: Change From Baseline in the CogState Global Cognitive Composite Score (GCCS) — -0.0902; -0.0722 Global Cognitive Composite Score — p=0.7363
Chronic Cluster Headache
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) — 106 Participants
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Primary: Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30 — 0; 49.5 percentage of subjects — p=<0.0001
Basal Cell Carcinoma
Primary: Number of Participants With Histologically Confirmed Complete Response — 25; 11 Participants
Epithelial Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
Primary: Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 5.59; 3.98 months — p=<0.0001
Cystic Fibrosis
Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) — -0.4; 8.9 percent predicted FEV1 — p=< 0.0001
Central Precocious Puberty
Primary: Percentage of Participants With Luteinising Hormone (LH) Suppression After Gonadotropin-Releasing Hormone (GnRH) Stimulation — 100 percentage of participants
Attention Deficit Hyperactivity Disorder
Primary: Percentage of Patients With Total ADHD-RS-V Reduction ≥25% — 95; 81 Participants — p=0.0199
Multiple Myeloma
Primary: Overall Survival (OS)
Induced Vaginal Delivery
Primary: Number of Uterine Contractions — 103; 112; 9; 15 contractions — p=0.44
Healthy
Primary: Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 24 Visits (Per-protocol [PP] Set) — 65; 58…